APAF Ltd (Australian Proteome Analysis Facility) Protein analysis and Quantitation
Overview
APAF Ltd was established in 1995 by grants from the Australian Federal and State governments. In 2007 this funding was provided through the National Collaborative Research Infrastructure Stratergy (NCRIS). APAF specializes in using the most advanced high-throughput, functional proteomics technologies to generate critical discovery and intellectual property in partnership with world leaders in medicine, science and agriculture.
Now as part of Bioplatforms Australia we have access to all technologies involved in Systems Biology, Genomics, Proteomics, Metabolomics and Bioinformatics.
Competitive advantages
APAF is a fully integrated, multi-hub, proteomics consortium offering an extensive range of advanced functional proteomics technologies and expertise. APAF was the first contract proteomics facility in operation worldwide and has more than 15 years of experience offering collaborators first-rate cutting-edge proteomics services throughout the world.
Partners
APAF has established many strategic partnerships with industry—including but not restricted to Bio-Rad, Applied Biosystems and 5 of the major Pharmaceutical companies world wide. APAF has been involved in more than 350 collaborations (many from outside Australia) in total resulting in Papers in Journals such as Cancer Research and PNAS.
Number of employees: 22
Main business focus/
Listing by sector:
- Service Provider
- AgBio - Plant
- Biodiscovery
- Diagnostics
- Industrial Biotechnology
Competitive Advantages
APAF is a fully integrated, multi-hub, proteomics consortium offering an extensive range of advanced functional proteomic technologies and expertise. APAF was the first contract proteomics facility in operation worldwide and has more than 10 years of experience offering collaborators first-rate cutting-edge proteomics services throughout the world.
Technology/IP
In addition to conventional proteomics technologies, APAF has a broad range of mass spectrometry capabilities including quantitation using MRM Assays, comparative (cell) proteomics using SILAC and iTRAQ , the removal of high abundance proteins, the ability to measure atto-mole level of Protein with new a STS platform, and just recently multiplexing bioassay capability using luminex technologies. Glycan characterisation of therapeutic recombinant proteins and antibodies is the most recently added service.
APAF has a number of examples of recent, successful partnerships across medicine, agriculture and science - including projects in cancer chemoresistance, response to drug therapy, cardiology, bacterial pathogenesis, ageing, neurological damage and agricultural crop productivity.
Partnering Opportunities
APAF is keen to explore collaborative and partnership opportunities with any industry or centre of excellence. We are especially interested in the Agricultural Biotech, Small to Medium Biotech, Pharmaceutical and Nutraceutical companies as well large research facilities involved in Life Sciences and those organisations producing therapeutic recombinant proteins.
Partnering Needs
APAF can offer some of the most advanced proteomic services if you need them along with experimental design to get the most from your contracted work. We can also show we offer the most accurate quantitation and identification (based on external surveys).
Contact Details
| Contact person | Lindsay Woods |
|---|---|
| Job Title | Director Business Development |
| Address | Lvl 1, 3 Innovation Road |
| Macquarie University | |
| City/Suburb | Sydney |
| State | New South Wales |
| lwoods@proteome.org.au | |
| Phone | +61 2 9805 3175 |
| Fax | +61 2 9850 6200 |
| Website | http://www.proteome.org.au |
